References: Importance of cytogenetic surveillance in leukemias with a designer therapy

Views

CrossRef citations to date

Altmetric

References

Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R, et al. Chronic myeloid leukemia, BCR/ABL studies and myelo proliferative disorders induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005; 19: 1573–1578
PubMed Web of Science ®Google Scholar
Evans G, Grimwade D, Prentice H G, Simpson N. Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid. Br J Haematol 1997; 98: 437–439
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Importance of cytogenetic surveillance in leukemias with a designer therapy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Importance of cytogenetic surveillance in leukemias with a designer therapy

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date